MONTREAL -- (BUSINESS WIRE) -- Angiochem, a clinical stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier (BBB), today announced that an abstract on its most advanced product candidate, ANG1005, has been selected for presentation at the 2013 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference being held October 20-22, 2013 in Boston, MA.
(Abstract/Poster #B76): Monday, October 21, 2013, 12:30-3:00 p.m. ET, “A Phase II Study of ANG1005, a Novel, Brain-Penetrant Taxane Derivative, in Breast Cancer Patients with Brain Metastases,” Nancy U. Lin, MD., Clinical Director of the Breast Cancer Treatment Center, Dana Faber Cancer Institute, Poster Session B, Clinical Trials, Exhibit Hall C-D.
ANG1005 is a novel targeted taxane derivative and represents the first oncology product to leverage the (LRP-1) pathway to cross the blood-brain barrier (BBB) and enter cancer cells. ANG1005 has been studied in over 200 patients in three clinical studies; two Phase 1 studies demonstrating tolerability similar to paclitaxel and encouraging signs of activity and a Phase 2 study the results of which will be reported at the 2013 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference. A Phase 2 clinical program with ANG1005 has been developed by Angiochem to further confirm the clinical activity observed in these earlier studies.
Angiochem is a clinical-stage biotechnology company discovering and developing new breakthrough peptide drug conjugates that leverage the LRP-1 mediated pathway to cross the BBB to treat neurological diseases. These new compounds have the potential to address significant medical needs, many of which are insurmountable due to the fundamental physiological challenge posed by the BBB.
Angiochem is developing a focused product pipeline, including small molecules and biologics, for the potential treatment of a wide range of CNS diseases, including brain cancer, brain metastases, lysosomal storage diseases and pain. Founded in 2003, Angiochem maintains headquarters in Montreal, Canada. For additional information about the Company, please visit http://www.angiochem.com.